ARQT Earnings
Latest Revenue129.9M
Latest Net Income15.0M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.11 | 129.9M | 15.0M | +59.3% | +184.6% |
| Q1 2026 | -$0.09 | 105.4M | -11295000 | +60.1% | +55.0% |
| Q4 2025 | $0.14 | 129.5M | 17.4M | +81.5% | +255.6% |
| Q3 2025 | $0.06 | 99.2M | 7.4M | +121.7% | +118.2% |
| Q2 2025 | -$0.13 | 81.5M | -15886000 | +164.1% | +69.0% |
| Q1 2025 | -$0.20 | 65.8M | -25060000 | +32.8% | +37.5% |
| Q4 2024 | -$0.09 | 71.4M | -10788000 | +427.6% | +87.3% |
| Q3 2024 | -$0.33 | 44.8M | -41537000 | +17.4% | +54.8% |
| Q2 2024 | -$0.42 | 30.9M | -52332000 | — | — |
| Q1 2024 | -$0.32 | 49.6M | -35382000 | — | — |
| Q4 2023 | -$0.71 | 13.5M | -66284000 | — | — |
| Q3 2023 | -$0.73 | 38.1M | -44765000 | — | — |
Arcutis Biotherapeutics (ARQT) — Earnings